Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/455)
-
Publication number: 20110268679Abstract: Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives.Type: ApplicationFiled: July 11, 2011Publication date: November 3, 2011Inventor: David SHERRIS
-
Publication number: 20110263920Abstract: The present invention relates to methods for treating cell proliferation disorders comprising (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated, (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder, and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferationType: ApplicationFiled: July 14, 2009Publication date: October 27, 2011Applicants: Duke University, Immunolight, LLCInventors: Frederic A. Bourke, JR., Tuan Vo Dinh
-
Publication number: 20110262457Abstract: Methods for increasing the generation of IL-17-producing T cells (TH17) in vivo and in vitro, and enriched populations of TH17 cells for the treatment of diseases benefiting from an induced or enhanced immune response, e.g., infection and cancer.Type: ApplicationFiled: March 19, 2009Publication date: October 27, 2011Inventors: Howard Weiner, Francisco J. Quintana
-
Publication number: 20110262535Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: ApplicationFiled: July 1, 2011Publication date: October 27, 2011Applicant: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Publication number: 20110263695Abstract: An NFAT signal inhibitor and the like are provided. An NFAT signal inhibitor and the like, containing, as an active ingredient, at least one compound selected from the group consisting of a coumarin derivative represented by formula [where in the formula (I), R1 and R2, which may be identical with or different from each other, each represent a hydrogen atom or a group represented by formula (II) (where in the formula (II), R3 represents a linear or branched alkyl or alkenyl group having 1 to 20 carbon atoms)] and pharmacologically acceptable salts thereof.Type: ApplicationFiled: October 21, 2009Publication date: October 27, 2011Applicant: KAO CORPORATIONInventors: Mitsuyoshi Sakasai, Yusuke Shibuya, Azumi Nagasawa
-
Publication number: 20110262362Abstract: The present invention provides methods to reduce or inhibit weight gain by administering inhibitors of the SirT1 protein to a subject. Methods to identify such inhibitors are also disclosed.Type: ApplicationFiled: October 9, 2009Publication date: October 27, 2011Inventors: Yansong Gu, Hongzhi Li
-
Publication number: 20110263694Abstract: The invention relates to xanthone derivatives of formula (IA) or (IB) and their use for manufacturing a medicament for cancer, and in particular for chemotherapeutic resistant cancer. More particularly, the invention relates to compounds and compositions comprising such xanthone derivatives for the prevention and/or treatment for chronic leukemia and, for example, for chronic lymphocytic leukemia (CLL) or B-lymphoma.Type: ApplicationFiled: April 6, 2009Publication date: October 27, 2011Applicants: MUSEUM NATIONAL D'HISTOIRE NATURELLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Jean-Pierre Kolb, Faouzia Menasria, Christian Billard, Michèle Meyer, Anatole Guy Azebaze, Augustin Ephrem Nkengfack
-
Publication number: 20110250296Abstract: A formulation or preparation for treating and preventing arterial and venous thrombi is provided. This preparation includes a non-metal containing photodynamic dye and a fat soluble vitamin. A method of administration for treatment and prophylaxis of arterial and venous thrombi is also provided. This method includes steps of: combining a non-metal containing photodynamic dye and a fat soluble vitamin; combining the non-metal containing photodynamic dye and fat soluble vitamin with a sodium solution; and administering the combination of non-metal containing photodynamic dye, fat soluble vitamin, and sodium solution as an intravenous drip.Type: ApplicationFiled: June 23, 2011Publication date: October 13, 2011Inventor: David E. Winslow
-
Patent number: 8034838Abstract: The composition for treating neurological disorders such as Alzheimer's Disease is provided. The composition includes a modified flavonoid compound having enhanced binding affinity to metabolic modulating enzymes. The composition is effective to down-regulate beta- and gamma-secretase and up-regulate alpha secretase, which results in a reduction in amyloid proteins.Type: GrantFiled: May 29, 2009Date of Patent: October 11, 2011Inventors: Daryl Lee Thompson, Milton Joseph Ahrens
-
Publication number: 20110243917Abstract: The present invention relates to a composition comprising PKC agonist as an active ingredient. More precisely, the present inventors confirmed that absence seizure specific SWD was reduced by administrating PKC agonist into an animal model. Therefore, the composition of the present invention comprising PKC agonist as an active ingredient can be effectively used for the prevention and treatment of absence seizure and for the production of health improving functional food.Type: ApplicationFiled: August 5, 2010Publication date: October 6, 2011Inventors: Eunji Cheong, Hee-Sup Shin, Yihong Zheng, Kyoobin Lee, Jungryun Lee, Seongwook Kim, Maryam Sanati, Sukyung Lee, Yeon-Soo Kim
-
Publication number: 20110236400Abstract: Disclosed are novel gamma secretase inhibitors of the formula. Also disclosed are methods of inhibiting gamma-secretase, methods of treating neurodegenerative diseases, and methods of treating Alzheimer's Disease. Also disclosed are processes for preparing alkenes in one reaction step using a mixture of an aldehyde (or ketone) and an alkyl substituted with two electron withdrawing groups, and reacting the mixture with: (a) a sulfonyl halide (e.g., a sulfonyl chloride) and a basic tertiary amine, or, (b) a sulfonyl anhydride and a basic amine, or (c) an aryl-C(O)-halide and a basic tertiary amine, or (d) an aryl-C(O)—O—C(O)-aryl and a basic tertiary amine, or (e) an heteroaryl-C(O)-halide and a basic tertiary amine, or (f) a heteroaryl-C(O)—O—C(O)-heteroaryl and a basic tertiary amine.Type: ApplicationFiled: July 1, 2008Publication date: September 29, 2011Inventors: Wen-Lian Wu, Thomas A. Bara, Duane A. Burnett, John W. Clader, Martin S. Domalski, Yan Jin, Hubert B. Josien, Hongmei Li, Xian Liang, Dmitri A. Pissarnitski, Thavalakulamgara K. Sasikumar, Jesse K. Wong, Ruo Xu, Zhiqiang Zhao, Paul E. McNamara
-
Publication number: 20110229495Abstract: The present invention provides a new method for the prediction of, or diagnosis of, auto-immune diseases, thereby alerting the subject to the presence of, or propensity to develop, an auto-immune disease so that preventative or therapeutic regiments may be initiated or changed so as to treat, modulate or prevent expansion of the CD4loCD40hi T cell population responsible for the destructive inflammation. The invention also discloses agents which modulate, treat or prevent expansion of CD4loCD40hi T cells. In one embodiment, the method is predictive of type 1 diabetes.Type: ApplicationFiled: March 3, 2009Publication date: September 22, 2011Inventor: David H. Wagner
-
Publication number: 20110224170Abstract: Disclosed is the use of pyranopyranone derivatives of formula wherein R1, R2, R3, R4 and R5 independently of one another are hydrogen; C1-C30alkyl, C2-C30alkenyl, or C3-C12cycloalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C6-C20aryl, which may be substituted by one or more G; C4-C20heteroaryl, which may be substituted by one or more G, C2-C18alkenyl, C2-C18alkynyl, C7-C25aralkyl, or —CO—R6; —SiR8R9R10; or R4 and R5 together form a five or six membered ring; or R3 and R4 together form a five or six membered ring; D is —CO—; —COO—; —S—; —SO—; —SO2—; —O—; —NR7—; —SiR8R9—; —POR10—; —CR12?CR13—; or —C?C—; and E is —OR6; —SR6; —NR14R15; —NR14COR15; —COR6; —COOR6; —CONR14R15; —CN; halogen; or OSO3R11; SO3R11; SO2R11; PO3(R11)2; OPO3(R11)2; G is E; C1-C18alkyl, which is optionally interrupted by D; C1-C18 perfluoroalkyl; C1-C18alkoxy, which is optionally substituted by E and/or interrupted by D; wherein R6 is H; C6-C18aryl which is optionally substituted by OH, C1-C30alkyType: ApplicationFiled: February 16, 2011Publication date: September 15, 2011Applicant: BASF SEInventors: Barbara Wagner, Janina Purschwitz, Karin Bieler
-
Publication number: 20110224146Abstract: The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents.Type: ApplicationFiled: May 23, 2011Publication date: September 15, 2011Inventors: Timothy P. Tully, Filippo Cavalieri
-
Patent number: 8017648Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:Type: GrantFiled: December 27, 2007Date of Patent: September 13, 2011Assignee: Infinity Pharmaceuticals, Inc.Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin Tremblay
-
Publication number: 20110217202Abstract: The present invention provides a lens care kit for disinfecting and/or cleaning contact lenses. The lens care kit of the invention comprising: (1) a lens care solution; (2) a lens case for holding the lens care solution and a contact lens immersed in the lens care solution; (3) a singlet oxygen-generating agent which is dissolved or dispersed in a lens care solution; and (4) a light irradiation source for irradiating the singlet oxygen-generating agent for a period of time sufficient to produce a sufficient amount of singlet oxygen in the lens care solution to disinfect the contact lens.Type: ApplicationFiled: March 7, 2011Publication date: September 8, 2011Inventor: Lynn Cook Winterton
-
Publication number: 20110218239Abstract: The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogues, and in particular, the flavone acetic acid analogue, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise an antimicrobial therapeutic agent for the treatment of viral infections of DNA and RNA viruses in humans and non-human animals. The invention is especially suitable for use in a process of treating and preventing infection by, for example, rhinoviruses, enteroviruses, and influenza viruses.Type: ApplicationFiled: March 14, 2011Publication date: September 8, 2011Applicant: University of Maryland BaltimoreInventors: Stefanie N. Vogel, Zachary J. Roberts, Leah E. Cole, Jorge Blanco
-
Publication number: 20110201678Abstract: This invention relates to novel compounds that are xanthenone-4-acetic acid derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel xanthenone-4-acetic acid derivatives that are derivatives of AS 1404. This invention also provides compositions comprising one or more compounds of this invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a vascular disrupting agent, such as AS 1404.Type: ApplicationFiled: October 16, 2009Publication date: August 18, 2011Inventor: Craig E. Masse
-
Patent number: 7998541Abstract: The present invention relates to benzochromene derivatives of the formula I where the various parameters have the meaning indicated in the text, and to liquid-crystal media which comprise these compounds, and to the use of the media in electro-optical displays, in particular in TN, OCB, LCOS and/or IPS-LCDs, and to the use of the compounds and physiologically acceptable derivatives thereof as therapeutic active ingredients.Type: GrantFiled: December 5, 2006Date of Patent: August 16, 2011Assignee: Merck Patent GmbHInventors: Andreas Taugerbeck, Elvira Montenegro, Atsutaka Manabe, Herbert Plach
-
Publication number: 20110190229Abstract: A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other.Type: ApplicationFiled: January 28, 2011Publication date: August 4, 2011Inventors: Seth J. Orlow, Li Ni Komatsu
-
Publication number: 20110190244Abstract: The invention provides a method of treating and/or preventing a toxicity associated with epidermal growth factor receptor (EGFR) inhibitor therapy in a subject, the method comprising administering to the subject an effective amount of a steroid sulfatase (STS) inhibitor. The toxicity may be ocular toxicity; or dermatologic toxicity, such as papulopustular rash. The EGFR inhibitor may be selected from the group consisting of: a small molecule; an antibody or derivative or fragment thereof; another agent that targets the extracellular or intracellular domain of the EGFR, such as a tyrosine kinase inhibitor selected from the group consisting of: erlotinib; gefitinib; lapatinib; and any combination thereof. The EGFR inhibitor may also be antibody selected from the group consisting of: cetuximab; panitumumab; and any combination thereof.Type: ApplicationFiled: October 26, 2010Publication date: August 4, 2011Applicant: Peter MacCallum Cancer InstituteInventor: John R. Zalcberg
-
Publication number: 20110178153Abstract: Methods of treating or preventing chemoresistance or relapse growth of cancer cells are provided. Methods of treating or preventing resistance to tyrosine kinase based chemotherapeutic treatment in hematologic and solid tumors are provided. BCR-ABL drug resistance in chronic myelogenous leukemia (CML) and models for conducting further study on the same are presented. The methods comprise administering a therapeutically effective amount of one or more SIRT1 modulators to the cells or subject in need thereof. The methods may be administered in combination with, prior to or subsequent to chemotherapy or may be administered to counteract the effect of a spontaneous genetic mutation. Methods of using SIRT1 inhibitors to treat or prevent insulin and transferrin-induced resistance are also presented. A novel cell model to study mechanisms of acquired chemoresistance is also provided.Type: ApplicationFiled: February 5, 2008Publication date: July 21, 2011Inventor: Wenyong CHEN
-
Patent number: 7981438Abstract: Methods of killing mosquito larvae and controlling an adult mosquito population by using ?-mangostin, 3,6,8-yrihydroxy-2-methoxy-1,7-bis(3-methylbut-2-enyl)xanthen-9-one, or a salt, solute, hydrate or solvate thereof. Mosquito larvae are killed by contacting a lethal dose of ?-mangostin with mosquito larvae. Adult mosquito populations are controlled by treating a mosquito larvae population with a lethal dose of ?-mangostin.Type: GrantFiled: May 30, 2008Date of Patent: July 19, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Que Lan, Min-Sik Kim
-
Publication number: 20110171195Abstract: Methods and compositions are provided for treating a urinary tract infection (UTI). The methods involve administering to a subject in need thereof a cAMP elevator or agent that mimics cAMP, particularly a labdane diterpene such as forskolin or a derivative or analog thereof in a therapeutically effective amount to treat a UTI. The methods may further include administration of at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs. Compositions of the invention include pharmaceutical compositions and kits for treating a UTI in a subject in need thereof that include therapeutically effective amounts of at least two cAMP elevators, particularly where one of the cAMP elevators is a labdane diterpene such as forskolin or a derivative or analog thereof.Type: ApplicationFiled: June 12, 2008Publication date: July 14, 2011Applicant: Duke UniversityInventors: Soman N. Abraham, Brian L. Bishop, Matthew J. Duncan, K. Ranga Rama Krishnan, Jeongmin Song, Guojie Li, David A. Zaas
-
Publication number: 20110171300Abstract: A compound of formula (I) wherein R is selected from (i) a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, which is optionally substituted by one or more groups independently selected from halo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; (ii) (C1-C6)alkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; (iii) (C1-C6)alkyl substituted by (C3-C13)cycloalkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; and (iv) (C3-C13)cycloalkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl.Type: ApplicationFiled: February 14, 2008Publication date: July 14, 2011Applicant: RESOLUTION CHEMICALS LIMITEDInventors: Parveen Bhatarah, Kevin John Batchelor, Derek Mchattie, Alan Kenneth Greenwood
-
Publication number: 20110172185Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.Type: ApplicationFiled: August 22, 2009Publication date: July 14, 2011Inventors: Masanori Baba, Yuichi Hashimoto
-
Patent number: 7977377Abstract: The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders.Type: GrantFiled: May 24, 2007Date of Patent: July 12, 2011Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Miao-Kun Sun, Daniel L. Alkon, Thomas J. Nelson
-
Publication number: 20110165125Abstract: The invention provides methods for one or more of enhancing energy metabolism, promoting healthy energy metabolism, maintaining healthy energy metabolism, preventing conditions that result in a decline or deficiency in energy metabolism, treating conditions that result in a decline or deficiency in energy metabolism, and preventing the accumulation of excess body fat in animals without reducing energy intake by the animals. The methods comprise administering isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day.Type: ApplicationFiled: August 10, 2009Publication date: July 7, 2011Inventor: Yuanlong Pan
-
Publication number: 20110166217Abstract: A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn.Type: ApplicationFiled: March 14, 2011Publication date: July 7, 2011Inventors: Chao Hsiang CHEN, Mei Yin CHIEN, Wen Mei FU, Jin-Ming CHANG
-
Publication number: 20110160298Abstract: A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn.Type: ApplicationFiled: March 14, 2011Publication date: June 30, 2011Inventors: Chao Hsiang CHEN, Mei Yin Chien, Wen Mei Hu, Jin-Ming Chang
-
Publication number: 20110151031Abstract: Xanthone compositions are provided herein. Formulations containing such compositions and methods of using such formulations and compositions are also provided. The present description additionally sets forth processes for making one or more compositions including compositions capable of promoting collagen production, antioxidant compositions, and anti-inflammatory compositions.Type: ApplicationFiled: August 18, 2009Publication date: June 23, 2011Applicant: DBC, LLCInventor: Yoshihiro Futamura
-
Publication number: 20110144193Abstract: The present invention relates to the effects of the epimeric mixture of cinchonains Ia and Ib on pathologies that involve alterations in the cardiovascular system, essentially in combating, preventing and reverting ventricular fibrillation in human beings and animals, especially for combating spontaneous or electric-stimulus-induced ventricular fibrillation, to revert spontaneous or electric-stimulus-induced ventricular fibrillations, for preventing ventricular fibrillation, for the treatment of ventricular fibrillation of any etiology or for the treatment of post-fibrillation to maintain normal cardiac rhythm. The present invention further relates to methods for the synthesis of an epimeric mixture of the chemical substances cinchonain Ia and Ib. The present invention also relates to the use of these chemical substances in reverting/combating ventricular fibrillation and/or in protecting against ventricular fibrillation.Type: ApplicationFiled: November 16, 2010Publication date: June 16, 2011Inventors: Ney Osvaldo Silva Filho, Irineu Tadeu Velasco, Augusto Scalabrini Neto, Luiz Pianowski
-
Publication number: 20110144194Abstract: Compounds of general formula (I) and (II) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 have the meanings given in the specification, are useful in the treatment of neurodegenerative disease.Type: ApplicationFiled: April 22, 2009Publication date: June 16, 2011Inventors: Djalil Coowar, Emmanuel Couche, Eric Koncina
-
Publication number: 20110129537Abstract: A functionalized nanoparticle, having a core, optionally having a shell on at least a portion thereof, wherein the core contains a material that can convert applied X-ray energy into emitted UV energy and wherein the shell, when present, contains a plasmonics active material; wherein the nanoparticle has on a surface thereof at least one psoralen compound capable of activation by the emitted UV energy, and the use of the functionalized nanoparticle in a method of treating a cell proliferation disorder such as cancer.Type: ApplicationFiled: July 26, 2010Publication date: June 2, 2011Applicant: Duke UniversityInventors: Tuan VO-DINH, Jon Scaffidi, Molly Gregas, Benoit Lauly
-
Publication number: 20110124502Abstract: Embodiments of the present invention provide compositions for controlling a target pest including a first agent and a second agent comprising a pest control product or a signal cascade modulator, wherein the first agent and the second agent act synergistically to control the target pest. The first agent can be capable of interacting with a receptor in the target pest. The pest control product can have a first activity against the target pest when applied without the active agent and the compositions can have a second activity against the target pest; and the second activity can be greater than the first activity. Embodiments of the invention can include compositions that modulate the signal cascade initiated by the binding of ligands to, for example, cell surface receptors. Methods of screening such compositions are also disclosed.Type: ApplicationFiled: March 19, 2009Publication date: May 26, 2011Inventor: Essam Enan
-
Publication number: 20110118343Abstract: Antitumoral compounds of general formula I: wherein R1-R14 and the lines take permitted meanings for use in the treatment of cancer.Type: ApplicationFiled: July 2, 2009Publication date: May 19, 2011Applicant: Pharma Mar, S. A.Inventors: José Fernando Reyes Benítez, Gloria Crespo Sueiro, Rogelio Fernández Rodríguez, Andrés Francesch Solloso, María del Carmen Cuevas Marchante
-
Publication number: 20110117202Abstract: Methods and systems for producing a change in a medium. A first method and system (1) place in a vicinity of the medium at least one upconverter including a gas for plasma ignition, with the upconverter being configured, upon exposure to initiation energy, to generate light for emission into the medium, and (2) apply the initiation energy from an energy source including the first wavelength ?1 to the medium, wherein the emitted light directly or indirectly produces the change in the medium. A second method and system (1) place in a vicinity of the medium an agent receptive to microwave radiation or radiofrequency radiation, and (2) apply as an initiation energy the microwave radiation or radiofrequency radiation by which the agent directly or indirectly generates emitted light in the infrared, visible, or ultraviolet range to produce at least one of physical and biological changes in the medium.Type: ApplicationFiled: November 10, 2010Publication date: May 19, 2011Applicants: Immunolight, LLC, Duke UniversityInventors: Frederic A. Bourke, JR., Zakaryae Fathi, Ian Nicholas Stanton, Michael J. Therien, Paul Rath Stauffer, Paolo MacCarini, Katherine Sarah Hansen, Diane Renee Fels, Cory Robert Wyatt, Mark Wesley Dewhirst
-
Publication number: 20110118224Abstract: The present invention is related to a use of a steroid sulfatase inhibitor in the manufacture of a medicament for preventing or inhibiting premature uterine contractions. Specifically, the present invention is related to steroid sulfatase inhibitors useful for the preparation of a pharmaceutical formulation for the modulation, notably the inhibition of pre-term labor.Type: ApplicationFiled: July 27, 2009Publication date: May 19, 2011Applicant: PREGLEM SAInventors: Ernest Loumaye, Valerie Cayron-Elizondo, Jean-Pierre Gotteland
-
Publication number: 20110105599Abstract: Therapeutic or preventive agents for ischemic nerve injury containing as the active ingredient compounds represented by the general formula [2]: wherein R1 and R4 are each independently hydrogen, carboxy, or alkoxycarbonyl; and R2 and R5 are each independently hydrogen, hydroxy group, or acyloxy group.Type: ApplicationFiled: November 5, 2010Publication date: May 5, 2011Applicant: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Kazuhito IKEDA, Toru Kimura
-
Publication number: 20110104177Abstract: The invention relates to histone deacetylase (HDAC) inhibitors to treat proliferative diseases. The present invention provides novel class III histone deacetylase inhibitors, in particular SIRT1 inhibitors, to reverse the silencing of hypermethylated genes, in combination with one or more other agents, in proliferative diseases such as cancer. The present invention provides methods of activating genes that are silenced by methylation in a subject by administering a HDAC inhibitor in combination with one or more agents.Type: ApplicationFiled: December 28, 2007Publication date: May 5, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Stephen Baylin, Kevin Pruitt
-
Patent number: 7935726Abstract: Provided are compounds of formula IA or IB: wherein R1 and R8 are independently optionally substituted hydrocarbyl groups; wherein (a) R1 contains a carbonyl group and a phenyl group, (b) R8 contains an optionally substituted adenine group, or (c) R8 contains an alkenyl group with from two to six carbon atoms; R10 is H, —OH, —OR or ?O; R6 is selected from the group consisting of: H, OH, alkyl, alkenyl, alkynyl, an aromatic ring system, amino, sulfhydryl, sulfonyl, NH2 and OCOR; R2 is selected from the group consisting of: H, —OH and lower alkyl; R is H or an optionally substituted hydrocarbyl group, and pharmaceutically acceptable salts or esters of the foregoing, as well as isomers thereof.Type: GrantFiled: April 29, 2004Date of Patent: May 3, 2011Assignee: Kansas State University Research FoundationInventor: Duy H. Hua
-
Publication number: 20110092584Abstract: The present invention relates to cannabinoic quinone compounds, and especially to their medical use. In particular five cannabinoic quinones, designated HU-331, HU-336, HU-345, HU-395 and HU-396 are herein described as active agents in pharmaceutical compositions. Said compounds and compositions thereof are intended for the treatment of inflammatory, infectious, auto-immune and particularly hyperproliferative disorders. Thus, the compounds of the invention may be used as anti-tumor agents, or for the treatment of cancer. Furthermore, three of these compounds, HU-345, HU-395 and HU-396, are novel cannabinoic quinones and thus are also claimed herein.Type: ApplicationFiled: January 14, 2005Publication date: April 21, 2011Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Raphael Mechoulam, Natalya M. Kogan, Ruth Rabinowitz, Michael Schlesinger
-
Publication number: 20110091387Abstract: The RhoE GTPase pathway has been identified as a target for screening and treatment methods for the prevention and/or reduction of short- and long-term UVB-induced skin damage, e.g., the prevention and/or reduction of UVB-induced wrinkles. The invention thus features screening and treatment methods for prevention or reduction of UVB-induced sin damage, and related compositions, e.g., cosmetic compositions.Type: ApplicationFiled: November 17, 2008Publication date: April 21, 2011Applicants: THE GENERAL HOSPITAL CORPORATION, SHISEIDO CO., LTD.Inventors: Sam W. Lee, Lakshmi Raj, Anna I. Mandinova, Haruhi Iwaki, Yuji Katsuta, Jotaro Nakanishi
-
Publication number: 20110092585Abstract: The present invention provides a novel pharmaceutical composition consisting of a combination of three coumarinolignoids of formula 1, 2 and 3 isolated from the seeds of the plant Cleome viscosa along with a pharmaceutically acceptable carrier useful as a immunomodulator. The invention also describes the ability of the compounds to modulate humorral and cell mediated immune response. It further provides a process for the preparation of a novel pharmaceutical composition of the said three coumarinolignoids in an optimized ratio to modulate humorral and cell mediated immune response.Type: ApplicationFiled: September 1, 2010Publication date: April 21, 2011Applicants: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Suman Preet Singh Khanuja, Anirban Pal, Sunil Kumar Chattopadhyay, Mahendra Pandurang Darokar, Rajendra Prasad Patel, Anil Kumar Gupta, Arvind Singh Negi, Tanpreet Kaur, Sudeep Tandon, Atul Prakash Kahol, Ankur Garg
-
Publication number: 20110070224Abstract: A delivery device including at least one stinging capsule and methods of use are described.Type: ApplicationFiled: November 30, 2010Publication date: March 24, 2011Applicant: NanoCyte Inc.Inventors: Tamar LOTAN, Shimon Eckhouse
-
Publication number: 20110059170Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.Type: ApplicationFiled: July 16, 2010Publication date: March 10, 2011Applicant: OREXIGEN THERAPEUTICS, INC.Inventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Publication number: 20110054013Abstract: Disclosed are novel gamma secretase inhibitors of the formula: wherein at least one (e.g., 1-4, 1-3, 1-2, 2 or 1) H is replaced by deuterium. Also disclosed are methods of inhibiting gamma-secretase, methods of treating neurodegenerative diseases, and methods of treating Alzheimer's Disease.Type: ApplicationFiled: August 26, 2010Publication date: March 3, 2011Inventor: John W. Clader
-
Publication number: 20110044991Abstract: This invention relates to the use of antagonists of the hedgehog signaling pathway to induce apoptosis of lymphoma and myeloma cells and to treat subjects suffering from various forms of lymphoma or myeloma.Type: ApplicationFiled: September 27, 2006Publication date: February 24, 2011Applicant: IRM LLCInventors: Christine Dierks, Markus Warmuth
-
Publication number: 20110021618Abstract: Described herein are compositions and methods for preventing and/or treating fibrotic disorders employing one or more benzo[c]chromen-6-one derivatives.Type: ApplicationFiled: March 25, 2009Publication date: January 27, 2011Applicant: PALOMA PHARMACEUTICALS, INC.Inventor: David Sherris
-
Publication number: 20110008269Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.Type: ApplicationFiled: August 9, 2010Publication date: January 13, 2011Inventor: Michael M. Grunstein